ISH 2020: global hypertension practice guidelines
International ISH Current
2020 International Society of Hypertension Global Hypertension Practice Guidelines
Unger T, et al. Hypertension. 2020;75:1334–1357
DOI 10.1161/HYPERTENSIONAHA.120.15026 · Summary checked against the source: 2026-11
Why this one matters in Bangladesh
ISH 2020 gives two levels of care for every recommendation. Essential is the minimum standard for low-resource settings. Optimal is evidence-based best care. That makes it a practical reference where the full AHA or ESC work-up isn't available.
At a glance
- Hypertension is office BP ≥140/90 on repeated measurement. "High-normal" is 130–139/85–89. [p. 1336]
- Out-of-office thresholds: home ≥135/85; ambulatory 24-h ≥130/80, daytime ≥135/85, night ≥120/70. [p. 1336]
- Core drug strategy: low-dose ACEi/ARB + dihydropyridine CCB, then full dose, then add a thiazide-like diuretic, then spironolactone. [Fig. 4, p. 1343]
- Prefer single-pill combinations and once-daily dosing. [p. 1343–1344]
- Targets: at least a 20/10 reduction, ideally <140/90. If tolerated, <130/80 under 65 and <140/90 at 65 and over. Aim for control within 3 months. [Fig. 3, p. 1343]
Classification
Adapted from ISH 2020 Table 1 and Table 2 [p. 1336]
| Category | SBP | DBP | |
|---|---|---|---|
| Normal | <130 | and | <85 |
| High-normal | 130–139 | and/or | 85–89 |
| Grade 1 hypertension | 140–159 | and/or | 90–99 |
| Grade 2 hypertension | ≥160 | and/or | ≥100 |
| Method | Hypertension if |
|---|---|
| Office | ≥140 and/or ≥90 |
| ABPM 24-h average | ≥130 and/or ≥80 |
| ABPM daytime | ≥135 and/or ≥85 |
| ABPM night-time | ≥120 and/or ≥70 |
| Home BP | ≥135 and/or ≥85 |
When to start drugs
The flowchart starts from established hypertension (≥140/90). High-normal BP (130–139/85–89) is managed with lifestyle change; drugs are added only when there's a compelling indication. [p. 1336]
flowchart TD
A["Established diagnosis of hypertension<br/>lifestyle advice for all"] --> G1["Grade 1<br/>140–159 / 90–99"]
A --> G2["Grade 2<br/>≥160 / ≥100"]
G2 --> NOW2["Immediate drug treatment<br/>in all patients<br/>(essential and optimal)"]
G1 --> HR["Immediate drug treatment if high risk<br/>or CVD, CKD, DM or HMOD<br/>(essential and optimal)"]
HR --> LR["Low-to-moderate risk<br/>(no CVD, CKD, DM or HMOD)"]
LR -- Optimal --> OPT["Lifestyle for 3–6 months<br/>then drugs if BP still not controlled"]
LR -- Essential --> Q{"Limited drug availability?"}
Q -- No --> OPT
Q -- Yes --> ESS["Lower-risk patients: lifestyle for 3–6 months<br/>If BP still not controlled, and where possible,<br/>start drugs in those aged 50–80"]
Adapted from ISH 2020 Figure 2 [p. 1342]
Targets
Adapted from ISH 2020 Figure 3 [p. 1343]
| Target | ||
|---|---|---|
| Essential | Lower BP by at least 20/10, ideally to <140/90 | Aim for BP control within 3 months |
| Optimal, age <65 | <130/80 if tolerated (but >120/70) | |
| Optimal, age ≥65 | <140/90 if tolerated; consider an individualised target based on frailty, independence and likely tolerability |
Core drug-treatment strategy
Ideally use a single-pill combination (SPC) at every step. [Fig. 4, p. 1343]
flowchart TD
S1["Step 1: dual low-dose combination<br/>A + C"] --> S2["Step 2: dual full-dose combination<br/>A + C"]
S2 --> S3["Step 3: triple combination<br/>A + C + D"]
S3 --> S4["Step 4: resistant hypertension<br/>A + C + D + spironolactone 12.5–50 mg once daily<br/>or another drug"]
Adapted from ISH 2020 Figure 4 (optimal column) [p. 1343]
A = ACE inhibitor or ARB · C = dihydropyridine CCB · D = thiazide-like diuretic · Low dose usually means half the maximum recommended dose.
| Footnote in Figure 4 | Applies to | What it says |
|---|---|---|
| a | Step 1 | Consider monotherapy in low-risk grade 1 hypertension, the very old (≥80) or frailer patients |
| b | Steps 1–2 | Consider A + D after stroke, in the very elderly, in incipient HF or with CCB intolerance |
| c | Step 1 | Consider A + C or C + D in Black patients |
| d | Step 4 | Caution with spironolactone or other potassium-sparing diuretics if eGFR <45 or K⁺ >4.5 mmol/L |
| * | Step 4 | Alternatives to spironolactone: amiloride, doxazosin, eplerenone, clonidine or a beta-blocker |
Essential standard (limited resources)
- Use whatever drugs are available, with as many of the ideal characteristics as possible (Table 9: outcome evidence, once daily, affordable, well tolerated).
- Use free combinations if single pills aren't available or affordable.
- Use a thiazide if a thiazide-like diuretic isn't available.
- If DHP-CCBs aren't available or tolerated, use an alternative such as a non-DHP CCB (diltiazem or verapamil).
Beta-blockers (essential and optimal)
Consider a beta-blocker at any step when there's a specific indication: heart failure, angina, post-MI, atrial fibrillation, or younger women who are pregnant or planning a pregnancy.
Comorbidities [p. 1344–1345]
| Condition | Start drugs at | Target | Preferred drugs |
|---|---|---|---|
| Coronary artery disease | ≥140/90 | <130/80 (<140/80 in elderly) | RAS blocker, beta-blocker ± CCB |
| Previous stroke | ≥140/90 | <130/80 (<140/80 in elderly) | RAS blocker, CCB, diuretic |
| Heart failure | ≥140/90 | <130/80 but >120/70 | HFrEF: RAS blocker or ARNI, beta-blocker, MRA (CCB only if BP uncontrolled) |
| CKD | ≥140/90 | <130/80 (<140/80 in elderly) | RAS blocker first; add CCB, diuretic (loop if eGFR <30) |
Resistant hypertension [p. 1346]
Definition: office BP >140/90 on three or more drugs at optimal or maximally tolerated doses, including a diuretic, after excluding pseudoresistance and secondary causes. About half of apparent cases turn out to be pseudoresistance.
Recommended steps
- Exclude pseudoresistance: poor measurement technique, white-coat effect, non-adherence, poor drug choices. Exclude substances that raise BP.
- Screen for secondary causes.
- Optimise the diuretic: thiazide-like rather than thiazide, maximum tolerated dose. Use a loop diuretic if eGFR <30 or the patient is volume overloaded.
- Add low-dose spironolactone as the fourth drug if K⁺ <4.5 mmol/L and eGFR >45.
- If spironolactone isn't suitable: amiloride, doxazosin, eplerenone, clonidine or a beta-blocker.
- Manage in a specialist centre.
Hypertensive emergencies [Table 12 · p. 1349]
Adapted from ISH 2020 Table 12
| Presentation | How fast, and to what |
|---|---|
| Malignant hypertension (± TMA or acute kidney failure) | Over several hours: lower MAP by 20–25% |
| Hypertensive encephalopathy | Immediately: lower MAP by 20–25% |
| Acute ischaemic stroke, BP >220/120 | Within 1 h: lower MAP by 15% |
| Acute ischaemic stroke for thrombolysis, BP >185/110 | Within 1 h: lower MAP by 15% |
| Acute haemorrhagic stroke, SBP >180 | Immediately: SBP 130–180 |
| Acute coronary event | Immediately: SBP <140 |
| Acute cardiogenic pulmonary oedema | Immediately: SBP <140 |
| Acute aortic disease | Immediately: SBP <120 and heart rate <60 |
| Eclampsia, severe preeclampsia, HELLP | Immediately: SBP <160 and DBP <105 |
The most common first-line drugs in the table are labetalol and nicardipine. Aortic disease uses esmolol with a vasodilator. Pulmonary oedema uses nitroprusside or nitroglycerine with a loop diuretic. Eclampsia uses labetalol or nicardipine plus magnesium sulphate.
Clinical pearls
- ISH grades hypertension (grade 1 and 2). AHA uses stages; ESC uses categories.
- The ISH "normal" upper limit is 130/85, not 120/80.
- ISH's core combination is ACEi/ARB + CCB, with the diuretic added third.
- Spironolactone as the fourth drug needs K⁺ <4.5 and eGFR >45.
- In aortic dissection, the target includes heart rate <60.
Classes and levels of evidence
How ISH 2020 grades its recommendations. Adapted from ISH 2020 Introduction and Guideline Development Process [p. 1334–1336]. Hover over any class or level cited on this page to see what it means.
| Standard | Meaning |
|---|---|
| Essential | Minimum standard of care, for settings with limited resources, where optimal care isn't always possible |
| Optimal | Evidence-based standard of care, as set out in recent major guidelines |
ISH 2020 doesn't grade recommendations by class or level of evidence. Instead, where practical, it gives two standards of care. Where clinical evidence was limited or absent, especially for essential standards in low-resource settings, the committee used expert opinion.